Spots Global Cancer Trial Database for unresectable hepatocellular carcinoma
Every month we try and update this database with for unresectable hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China | NCT06315101 | Unresectable He... | Chinese Herbal ... | 18 Years - 85 Years | Guangzhou University of Chinese Medicine | |
| Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma | NCT04605185 | Unresectable He... | Donafenib Tosil... Toripalimab Inj... | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) | NCT05660213 | Unresectable He... | Huaier granule Atezolizumab + ... Camrelizumab+Ap... Sintilimab+Beva... | 18 Years - | Fudan University | |
| Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China | NCT06315101 | Unresectable He... | Chinese Herbal ... | 18 Years - 85 Years | Guangzhou University of Chinese Medicine | |
| Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | NCT02658019 | Hepatocellular ... | Pembrolizumab | 18 Years - | University of Miami | |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer | NCT05176223 | Advanced Hepato... Stage III Hepat... Stage IV Hepato... Unresectable He... | Computed Tomogr... Gallium Ga 68 G... Positron Emissi... | 18 Years - | Mayo Clinic | |
| Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | NCT05096715 | Unresectable He... | Atezolizumab Bevacizumab Stereotactic bo... | 18 Years - | Massachusetts General Hospital | |
| Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma | NCT05957640 | Unresectable He... | Yttrium-90 carb... | 18 Years - 75 Years | Zhongda Hospital | |
| Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma | NCT00829465 | Unresectable He... | Licartin Transcatheter a... | 18 Years - 85 Years | Eastern Hepatobiliary Surgery Hospital | |
| Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients | NCT04736121 | Unresectable He... BCLC Stage A He... BCLC Stage B He... BCLC Stage C He... | Resin microsphe... | 18 Years - | Sirtex Medical | |
| Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) | NCT02953743 | Unresectable He... | Lenvatinib | 18 Years - | Eisai Inc. | |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | NCT04605731 | BCLC Stage B He... BCLC Stage C He... Locally Advance... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Durvalumab Tremelimumab | 18 Years - | City of Hope Medical Center | |
| Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | NCT02658019 | Hepatocellular ... | Pembrolizumab | 18 Years - | University of Miami | |
| The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma | NCT03652467 | Hepatocellular ... | Conventional TA... Deferoxamine an... | 18 Years - | Jinan Military General Hospital | |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | NCT04175912 | Metastatic Chol... Metastatic Hepa... Stage III Hepat... Stage III Intra... Stage IIIA Hepa... Stage IIIA Intr... Stage IIIB Hepa... Stage IIIB Intr... Stage IV Hepato... Stage IV Intrah... Stage IVA Hepat... Stage IVB Hepat... Unresectable Ch... Unresectable He... Unresectable In... | Carboplatin Paclitaxel Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | NCT06360042 | Unresectable He... | Adebrelimab plu... Adebrelimab plu... Camrelizumab pl... | 18 Years - | Peking University Cancer Hospital & Institute | |
| Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | NCT04401800 | Hepatocellular ... Unresectable He... Metastatic Hepa... | Lenvatinib Tislelizumab | 18 Years - 70 Years | BeiGene | |
| Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | NCT00142467 | Hepatocellular ... | Gemcitabine Oxaliplatin Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | NCT06117891 | Unresectable He... | Atezolizumab Bevacizumab Durvalumab Tremelimumab, | 18 Years - | Bayer | |
| SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | NCT00503867 | Carcinoma, Hepa... Hepatoma | SIR-Spheres mic... | 18 Years - | Sirtex Medical | |
| TACE Study-Liver Embolization Perfusion (VGH Radiology LIU) | NCT02093104 | Unresectable He... Undergoing Chem... | 19 Years - | University of British Columbia | ||
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC | NCT04297254 | Carcinoma, Hepa... | Lenvatinib | 18 Years - | Eisai Inc. | |
| Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | NCT02989870 | HepatoCellular ... Unresectable He... Liver Cancer | Stereotactic Bo... Sorafenib Bavituximab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma | NCT05957640 | Unresectable He... | Yttrium-90 carb... | 18 Years - 75 Years | Zhongda Hospital | |
| HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC | NCT05582278 | Unresectable He... | D-TACE HAIC Lenvatinib tislelizumab | 18 Years - 75 Years | Second Affiliated Hospital of Nanchang University | |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | NCT05103904 | Recurrent Hepat... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Laboratory Biom... Lenvatinib | 18 Years - | Emory University | |
| Impact of Y90 Radiation Segmentectomy on HCC | NCT03248375 | Hepatocellular ... | Radiation Segme... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma | NCT01176604 | Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Yttrium Y 90 Gl... | - | M.D. Anderson Cancer Center | |
| Himalaya Early Access Program | NCT05345678 | Unresectable He... | Durvalumab Tremelimumab | 18 Years - | AstraZeneca | |
| Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | NCT02323906 | Carcinoma, Hepa... | CC-122 Sorafenib | 18 Years - | Celgene | |
| Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) | NCT03433703 | Carcinoma, Hepa... | Lenvatinib | 18 Years - | Eisai Inc. | |
| Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | NCT02323906 | Carcinoma, Hepa... | CC-122 Sorafenib | 18 Years - | Celgene | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| TACE Study-Liver Embolization Perfusion (VGH Radiology LIU) | NCT02093104 | Unresectable He... Undergoing Chem... | 19 Years - | University of British Columbia | ||
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer | NCT05176223 | Advanced Hepato... Stage III Hepat... Stage IV Hepato... Unresectable He... | Computed Tomogr... Gallium Ga 68 G... Positron Emissi... | 18 Years - | Mayo Clinic | |
| Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma | NCT06310590 | Unresectable He... | NRT6003 Injecti... | 18 Years - 80 Years | Chengdu New Radiomedicine Technology Co. LTD. | |
| Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan | NCT01411436 | Carcinoma, Hepa... | Sorafenib (Nexa... | - | Bayer | |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | NCT05103904 | Recurrent Hepat... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Laboratory Biom... Lenvatinib | 18 Years - | Emory University | |
| A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab | NCT04770896 | Unresectable He... | Atezolizumab Lenvatinib Sorafenib | 18 Years - | Hoffmann-La Roche | |
| Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma | NCT00142428 | Hepatocellular ... | Cetuximab | 18 Years - | Massachusetts General Hospital | |
| The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma | NCT03652467 | Hepatocellular ... | Conventional TA... Deferoxamine an... | 18 Years - | Jinan Military General Hospital | |
| Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) | NCT03433703 | Carcinoma, Hepa... | Lenvatinib | 18 Years - | Eisai Inc. | |
| A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | NCT00142467 | Hepatocellular ... | Gemcitabine Oxaliplatin Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT01004978 | Hepatocellular ... Unresectable He... | Cisplatin Computed Tomogr... Doxorubicin Hyd... Doxorubicin-Elu... Laboratory Biom... Magnetic Resona... Mitomycin Pharmacological... Placebo Adminis... Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | NCT03695250 | Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | IDO1 Inhibitor ... Nivolumab | 18 Years - | University of California, Davis | |
| HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure | NCT05135364 | Unresectable He... | Camrelizumab HAIC TKI | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Clinical Study of Precision TACE (P-TACE) With Surefire | NCT03345225 | Unresectable He... | SureFire Infusi... Standard Endhol... | 18 Years - | University of Miami | |
| Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | NCT00988741 | Unresectable He... | ARQ 197 Placebo | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | NCT05103904 | Recurrent Hepat... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Laboratory Biom... Lenvatinib | 18 Years - | Emory University | |
| A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma | NCT04829383 | Unresectable He... | Atezolizumab Bevacizumab | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab | NCT04770896 | Unresectable He... | Atezolizumab Lenvatinib Sorafenib | 18 Years - | Hoffmann-La Roche | |
| Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma | NCT05507632 | Unresectable He... | Donafenib plus ... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| TACE Study-Liver Embolization Perfusion (VGH Radiology LIU) | NCT02093104 | Unresectable He... Undergoing Chem... | 19 Years - | University of British Columbia | ||
| SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | NCT00503867 | Carcinoma, Hepa... Hepatoma | SIR-Spheres mic... | 18 Years - | Sirtex Medical | |
| Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma | NCT02006030 | Unresectable He... | ADI-PEG 20 Transarterial c... | 18 Years - | Polaris Group | |
| Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC) | NCT03289273 | Liver Neoplasms | Regorafenib (St... | - | Bayer | |
| Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma | NCT00142428 | Hepatocellular ... | Cetuximab | 18 Years - | Massachusetts General Hospital | |
| Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) | NCT03896646 | Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Computed Tomogr... Hepatobiliary I... Single Photon E... Yttrium Y 90 Gl... Yttrium-90 Micr... | 18 Years - | M.D. Anderson Cancer Center | |
| An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer | NCT00247676 | Liver Neoplasms Unresectable He... | Sunitinib (SU01... | 18 Years - | Pfizer | |
| Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma | NCT01176604 | Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Yttrium Y 90 Gl... | - | M.D. Anderson Cancer Center | |
| A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma | NCT04947956 | Unresectable He... | Camrelizumab | 18 Years - | Shanghai Zhongshan Hospital | |
| Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma | NCT01176604 | Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Yttrium Y 90 Gl... | - | M.D. Anderson Cancer Center | |
| Impact of Y90 Radiation Segmentectomy on HCC | NCT03248375 | Hepatocellular ... | Radiation Segme... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | NCT05199285 | BCLC Stage B He... BCLC Stage C He... Locally Advance... Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Ipilimumab Nivolumab | 18 Years - | Academic and Community Cancer Research United | |
| Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | NCT03942328 | Stage III Hepat... Stage III Intra... Stage IV Hepato... Stage IV Intrah... Unresectable He... Unresectable In... | Atezolizumab Bevacizumab External Beam R... Pheresis Pneumococcal 13... Therapeutic Aut... | 18 Years - | Mayo Clinic | |
| Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China | NCT06315101 | Unresectable He... | Chinese Herbal ... | 18 Years - 85 Years | Guangzhou University of Chinese Medicine | |
| Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | NCT05917431 | Unresectable He... Oligometastatic... | SBRT plus tisle... | 18 Years - | Peking University Cancer Hospital & Institute | |
| Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | NCT06360042 | Unresectable He... | Adebrelimab plu... Adebrelimab plu... Camrelizumab pl... | 18 Years - | Peking University Cancer Hospital & Institute | |
| Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | NCT00142467 | Hepatocellular ... | Gemcitabine Oxaliplatin Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan | NCT01411436 | Carcinoma, Hepa... | Sorafenib (Nexa... | - | Bayer | |
| BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | NCT03695250 | Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | IDO1 Inhibitor ... Nivolumab | 18 Years - | University of California, Davis | |
| DEB-TACE+HAIC vs. HAIC for Large HCC | NCT05263219 | Unresectable He... | dTACE-HAIC HAIC dTACE-HAIC prot... HAIC protocol | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma | NCT06310590 | Unresectable He... | NRT6003 Injecti... | 18 Years - 80 Years | Chengdu New Radiomedicine Technology Co. LTD. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
